P Seeman1, R Corbett, H H Van Tol. Show Affiliations » 1. Pharmacology Department, University of Toronto, Canada.
Abstract
Entities: Disease
Mesh： See more » Antipsychotic Agents/adverse effectsClozapine/metabolismDopamine/metabolismDopamine D2 Receptor AntagonistsHumansMuscarinic AntagonistsParkinson Disease, Secondary/chemically inducedParkinson Disease, Secondary/prevention & controlRadioligand AssayReceptor, Serotonin, 5-HT2AReceptors, Dopamine D2/metabolismReceptors, Dopamine D4Receptors, Muscarinic/metabolismReceptors, Serotonin/metabolismSerotonin Antagonists
Substances： See more » Antipsychotic AgentsDRD4 protein, humanDopamine D2 Receptor AntagonistsMuscarinic AntagonistsReceptor, Serotonin, 5-HT2AReceptors, Dopamine D2Receptors, MuscarinicReceptors, SerotoninSerotonin AntagonistsReceptors, Dopamine D4ClozapineDopamine
Year: 1998 PMID： 9327943 DOI： 10.1016/s1054-3589(08)60792-9
Source DB: PubMed Journal: Adv Pharmacol ISSN： 1054-3589